Empowering clinicians and patients in antipsychotic dose reduction for schizophrenia: the role of online tools Authors: Stefan Leucht, Alessandro Rodolico Published: 2025 Antipsychotic discontinuation remains a contested topic, with evidence offering both reassurance about side‑effects and warnings about relapse. We summarize the components of the debate and conclude that it is important to empower clinicians and patients to make their personal decisions and we direct readers to information centers such as www.illuminatum.com, www.psymatik.org and the APA website. First, the rates of relapse after stopping antipsychotics are high. Antipsychotics reduce relapse rates from 65% to 27% within one year1,2. This is one of the largest effects of drugs in medicine3,4. The effect is seen not only in chronic patients with multiple prior episodes, but also after a first episode and among those in remission. Even patients who have taken antipsychotics for 3–6 years before stopping medication in randomized trials2, and for up to 7 years according to registry studies, face a higher risk of relapse if they discontinue medication compared with those who continue treatment5. Second, dose reduction is associated with higher relapse rates. On average, standard doses such as 5 mg/day risperidone equivalent are sufficient6. There is considerable interindividual variability, meaning that some patients may do well on lower doses. However, dose–response meta-analyses of fixed doses have shown that the risk of relapse increases disproportionately below 5 mg/day risperidone equivalent. Reviews of dose-reduction studies have likewise found that the lower the dose, the higher the relapse risk7. Both older and more recent studies of “intermittent treatment”—stopping medication and restarting it at early signs of relapse—consistently reported relapse rates higher than those observed with continuous treatment8,9. Furthermore, national registry studies show that untreated patients have the poorest outcomes10. Thus, substantial dose reduction is a risky strategy. Third, antipsychotics have dose-related side effects11–14. However, not all antipsychotics produce the same side effects, and not all patients experience all of them—or consider them equally important. Switching to a different antipsychotic is generally safer than substantial dose reduction and may be tried before a substantial dose reduction15. Fourth, the debate about whether antipsychotic drugs cause brain volume loss is important but, in our view, remains unresolved. For example, one research group found that higher doses were associated with greater brain volume loss16. Yet, in the same cohort, they also observed that longer durations of relapse were linked to more brain volume loss17. This latter finding could suggest that preventing relapses is important. Fifth, the evidence on whether long-term outcomes improve after discontinuing antipsychotics is equivocal. The results of the Dutch HAMLETT study are difficult to interpret: functioning, as measured by the Global Assessment of Functioning (GAF), was better, but patients who initially discontinued antipsychotics ultimately had the same average doses as those who continued18. The findings of the 7-year follow-up study by Wunderink et al. 19 have been criticized on several grounds, and follow-up results from the UK RADAR study are not yet available9. Inevitably, all long-term follow-up studies in this field are not randomized, which introduces potential bias. Sixth, supersensitivity of dopamine receptors following antipsychotic treatment has been demonstrated in animal models, and at least one PET study in humans supports this finding20. Whether this supersensitivity is linked to rebound psychosis after discontinuation has not been clearly shown in patients. Nevertheless, antipsychotic withdrawal has been shown to produce rebound side effects21. Moreover, the leading hypothesis for the etiology of tardive dyskinesia involves dopamine receptor supersensitivity. Similarly, switching from D2 antagonists to partial agonists has been associated with transient psychotic symptoms in sensitized dopamine systems, and the risk appears higher with faster cross-titration22. Thus, breakthrough psychosis23 - that is, relapses despite ongoing antipsychotic treatment—could be explained by the same mechanism. Seventh, data suggest that the more relapses patients experience, the longer it takes for them to achieve remission, and that remission rates are lower after the first relapse compared to the initial episode24,25. This is what some experts mean when they describe relapses as “toxic” for the brain, implying that they should be avoided. However, the causal relationship between relapses and long-term outcomes has not been convincingly demonstrated26. Eighth, the course of schizophrenia is highly variable27,28. Approximately 25% of patients experiencing a first episode of psychosis are chronically ill from the outset29, while others follow a relapsing-remitting course, with wide variation in the number of psychotic episodes over time. Around 20% of patients may not experience a second psychotic episode within five years30,31. This observation suggests that one in five patients could receive unnecessary treatment, exposing them to potential adverse effects. Unfortunately, we lack predictors to identify who will follow a benign single-episode course versus transition to recurrent psychosis32. Ninth, relapsesis an outcome of intermediate severity. Reoccurrences of symptoms vary in severity; however, they are not fatal (except in cases of suicide). A comparison to heart transplantation may be illustrative: not all patients who stop immunosuppressants will experience organ rejection, but if rejection occurs, it is fatal. Some relapses of schizophrenia are severe, with dire consequences such as harm for the patient or others, prolonged hospitalization, loss of employment or relationships, and eventually further cognitive decline. Others are milder and can be effectively managed by restarting medication. Tenth, the dimensional nature of psychiatric disorders complicates the discussion. Psychiatric disorders can be defined as brain diseases whose exact causes remain unknown33. They are likely network-based dysfunctions rather than localized brain lesions. As a result, there is a continuum between normal functioning and severe illness; for example, 5-7% of the general population sometimes experience attenuated psychosis-like symptoms. Furthermore, symptom dimensions often overlap across disorders—for instance, individuals with schizophrenia can exhibit symptoms of affective disorders, and vice versa. Currently, we have no clinically useful biomarkers. If biomarkers existed, relapse could be defined more clearly, and discussions about relapse prevention could be more objective. What should be done in this dilemma? There is a “medication-free life” ideology that extends beyond psychiatry. It is an ideology because, if medication helps a patient remain well and is tolerable, it is irrational to stop it. We need to empower both clinicians and patients to make rational decisions. Patient and family psychoeducation is crucial34,35. Patients should always be informed that their risk of relapse doubles after stopping medication, and they should understand the potentially dire consequences of a relapse. If we put ourselves in a patient’s shoes, we might cautiously and very slowly (1-2 years tapering after 1 year in remission) want to explore whether we are among the approximately 20% who do not relapse after a first psychotic episode, taking into account the circumstances of our first episode. How severe (e.g. harm to myself or others) and how long was the index episode, response to treatment, side-effects, is there a job or a partner to lose and is there a personal support network that can intervene if warning signs appear. After a first relapse, we would probably be reluctant to discontinue medication unless side effects were unbearable. We would simply not like to be psychotic, be in and out of hospitals etc, but we would rather want to lead as normal a life as possible. If side-effects were pronounced, we would first want to switch to a medication with fewer side effects. If patients insist on reducing the dose or discontinuing medication, this should be done very gradually, thinking in months for each reduction step, allowing the brain to adapt to lower doses. Clinician engagement prevents unmonitored self-withdrawal, with meta-analytic evidence demonstrating that positive treatment attitudes and clinician support are protective against non-adherence36. Moreover, even low doses have some effect and are, therefore, preferable to none6. Some patients have told us that they do not like antipsychotics but if they go below, say, 50 mg /day of clozapine, psychosis starts again. Therefore, once side effects are tolerable after somewhat lowering the dose, patients should again be encouraged to continue treatment. Importantly, even if patients decide to reduce or discontinue antipsychotics, they should not be abandoned; instead, they should be closely supported throughout the process. Finally, it is obvious that the situation is complex. We, therefore, need to empower physicians and patients with easily accessible digital tools to manage schizophrenia. A wealth of evidence-based information and resources exists, but clinicians do not know about them, thus these tools need to be bundled. The platform www.illuminatum.com brings together many such digital tools. At its core is an evidence-based guideline that is “living,” meaning it is updated continuously. The platform also links to multiple resources, including: a visualization tool showing how relapse risk increases when antipsychotic doses are reduced, an early warning sign questionnaire, dose-conversion information, the “Shared-Decision-Making Assistant” for selecting medications, switchrx.com (a website specifically designed for switching antipsychotics), summaries of product characteristics, other guidelines such as APA37 or INTEGRATE38 (also see www.psymatik.com), SMI Adviser, a tool with detailed information on the use of long-acting injectable antipsychotics, open-source metacognitive training, a PowerPoint slide deck for immediate use in psychoeducation of patients and relatives, and many more resources. Further suggestions are welcome. Additionally, we aim to collect the experiences, tips and tricks of physicians, to effectively “co-create the guideline with its users.” This aligns with the ideal of integrating the best available evidence with clinical experience and patient preferences, as Evidence-Based Medicine, by its very definition, ought to39. We expect this tool to promote rational, effective decisions—particularly around controversial topics such as antipsychotic de‑prescription—and to enable shared decision‑making based on clear data. Author contributions S.L. conceived and designed the commentary and drafted the manuscript. A.R. critically revised the manuscript for important intellectual content. Both authors approved the final version of the manuscript and agree to be accountable for all aspects of the work. Competing interests In the last 3 years, S.L. has received honoraria as advisor and/or for lectures and/or for educational material from Alkermes, Angelini, Apsen, Eisai, Gedeon Richter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Merck Sharp and Dohme, Mitsubishi, Neurotorium, Novo Nordisk, Otsuka, Recordati, Roche, Rovi, Sanofi-Aventis, and TEVA. A.R. has no competing interests to declare. Footnotes Invited commentary for the special feature on Antipsychotic Discontinuation. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References